No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
ST Spring: Notice on Qinghai Spring\'s Response to the Shanghai Stock Exchange\'s “Supervisory Work Letter on Matters Relating to the Qinghai Spring Performance Forecast”
ST Spring: Qinghai Spring 2024 Annual Results Pre-loss Announcement
Qinghai Spring 2024 Annual Results Pre-loss Announcement
Special Treat Spring (600381.SH): Expected loss of 0.145 billion to 0.174 billion yuan for the 2024 fiscal year.
On January 16, Gelonghui reported that ST Chuntian (600381.SH) announced a performance pre-loss notice for 2024. The finance department's preliminary estimate indicates that the company expects the net income attributable to shareholders of the listed company to be between -0.145 billion yuan and -0.174 billion yuan, while the net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, is expected to be between -0.117 billion yuan and -0.146 billion yuan, which will result in a loss.
There's Reason For Concern Over Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) Massive 29% Price Jump
Despite Currently Being Unprofitable, Qinghai Spring Medicinal Resources Technology (SHSE:600381) Has Delivered a 39% Return to Shareholders Over 3 Years